The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for bumetanide nasal spray (RSQ-777) for the treatment of edema associated with congestive heart ...

Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model Research demonstrates distinct mechanisms for neonatal and post-pubertal ...

Bumetanide Nasal Spray (RSQ-777) is being developed as a convenient, outpatient-focused therapy for edema associated with congestive heart failure, as well as liver and kidney disease.